ALS Association Statement on VITALITY-ALS Results

November 21, 2017

Earlier today, Cytokinetics announced that its phase 3 trial of VITALITY-ALS (tirasemtiv) did not succeed in meeting its endpoints. Cytokinetics President and CEO Robert Blum stated: “While we are deeply disappointed by the results of VITALITY-ALS, we remain committed to people with ALS who are fighting this devastating disease and who need new therapies to slow the decline of respiratory function and muscle strength that are key hallmarks of disease progression.”

The ALS Association released the following statement:

We join the ALS community in being saddened by the results of the VITALITY-ALS trial. We are grateful that Cytokinetics has already expressed its commitment to finding new therapies for people with ALS and hopeful that its next treatment, which is currently in clinical trials, will be successful. We thank Cytokinetics for its unwavering support of the ALS community. The ALS Association continues to work with our partners to bring ALS treatments forward as soon as possible.

Powered by Blackbaud
nonprofit software